在评级胶质瘤中,实验ASL为基础的动脉血容量作为一种新型成像生物标志物。
Experimenting with ASL-based arterialized cerebral blood volume as a novel imaging biomarker in grading glial neoplasms.
发表日期:2023 Aug 07
作者:
Krishna Pratap Singh Senger, C Kesavadas, Bejoy Thomas, Ankita Singh, Gurpreet Singh Multani, Deepti An, Marc Label, Banerjee Suchandrima, David Shin
来源:
Brain Structure & Function
摘要:
灌注成像是用于分级胶质肿瘤的方法之一,在本研究中,我们评估了ASL灌注在脑胶质瘤分级中的作用。旨在评估多延迟ASL灌注中动脉化脑血容量(aCBV)在分级胶质肿瘤中的作用。该研究是一项前瞻性观察性研究,纳入了56例接受手术治疗的脑胶质瘤患者,仅评估了有胶质瘤阳性诊断的病例以评估新的诊断参数。在研究中,ASL衍生的标准化aCBV (naCBV)和T2*DSC衍生的标准化CBV (nCBV)在胶质肿瘤分级中显示出很高的相关性(Pearson相关系数值为0.94)。naCBV和nCBF也显示出很高的相关性(Pearson相关系数值为0.876)。该研究还提供了区分低级胶质瘤和高级胶质瘤的标准化aCBV(naCBV)、标准化CBV (nCBV)和T2* DCS衍生的标准化nCBF的截断值,分别为1.12、1.254和1.31。与ASL衍生的CBF相比,ASL衍生的aCBV还显示出更好的诊断准确性。据我们所知,这是迄今为止唯一一项使用多延迟ASL灌注衍生的aCBV作为胶质肿瘤分级的新型成像生物标志物的研究,并且显示出与T2* DSC灌注参数的高度统计相关性。
Perfusion imaging is one of the methods used to grade glial neoplasms, and in this study we evaluated the role of ASL perfusion in grading brain glioma.The aim is to evaluate the role of arterialized cerebral blood volume (aCBV) of multi-delay ASL perfusion for grading glial neoplasm.This study is a prospective observational study of 56 patients with glial neoplasms of the brain who underwent surgery, and only cases with positive diagnosis of glioma are included to evaluate the novel diagnostic parameter.In the study, ASL-derived normalized aCBV (naCBV) and T2*DSC-derived normalized CBV (nCBV) are showing very high correlation (Pearson's correlation coefficient value of 0.94) in grading glial neoplasms. naCBV and nCBF are also showing very high correlation (Pearson's correlation coefficient value of 0.876). The study also provides cutoff values for differentiating LGG from HGG for normalized aCBV(naCBV) of ASL, normalized CBV (nCBV), and normalized nCBF derived from T2* DCS as 1.12, 1.254, and 1.31, respectively. ASL-derived aCBV also shows better diagnostic accuracy than ASL-derived CBF.This study is one of its kind to the best of our knowledge where multi-delay ASL perfusion-derived aCBV is used as a novel imaging biomarker for grading glial neoplasms, and it has shown high statistical correlation with T2* DSC-derived perfusion parameters.